ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
67 152,93
0,32%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Celgene Corporation (CELG)

  7. Celgene Corporation (CELG) Actualités

CELG

Celgene (CELG)

Celgene Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CELG
DateHeureSourceTitreSymboleSociété
16/12/201913h30GlobeNewswire Inc.NexImmune Appoints Sol Barer as Chairman of the Board of DirectorsNASDAQ:CELGCelgene Corporation
21/11/201912h21PR Newswire (US)Amgen Completes Acquisition Of Otezla® (apremilast)NASDAQ:CELGCelgene Corporation
20/11/201922h18Business WireCelgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...NASDAQ:CELGCelgene Corporation
20/11/201920h09Business WireCELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...NASDAQ:CELGCelgene Corporation
19/11/201917h16PR Newswire (US)Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500NASDAQ:CELGCelgene Corporation
18/11/201923h10GlobeNewswire Inc.Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019NASDAQ:CELGCelgene Corporation
15/11/201923h39Dow Jones NewsFTC Requires Bristol-Meyers Squibb, Celgene to Divest Otezla as Condition of AcquisitionNASDAQ:CELGCelgene Corporation
15/11/201914h22Dow Jones NewsCelgene Gets CHMP Positive Opinion for Revlimid/Rituximab Combo in Follicular LymphomaNASDAQ:CELGCelgene Corporation
15/11/201913h30Business WireCelgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...NASDAQ:CELGCelgene Corporation
13/11/201904h28PR Newswire (Canada)Skyhawk Therapeutics annonce une deuxième entente de collaboration multicible avec Celgene pour découvrir et mettre au poin...NASDAQ:CELGCelgene Corporation
12/11/201915h00PR Newswire (US)Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...NASDAQ:CELGCelgene Corporation
08/11/201919h30Dow Jones NewsAcceleron Pharma Shares Gain Ground After FDA Approves ReblozylNASDAQ:CELGCelgene Corporation
08/11/201919h20Dow Jones NewsFDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood DisorderNASDAQ:CELGCelgene Corporation
08/11/201918h33Business WireFDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...NASDAQ:CELGCelgene Corporation
06/11/201922h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
06/11/201915h06Business WireCelgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...NASDAQ:CELGCelgene Corporation
31/10/201921h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CELGCelgene Corporation
31/10/201912h37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CELGCelgene Corporation
31/10/201912h30Business WireCelgene Reports Third Quarter 2019 Operating and Financial ResultsNASDAQ:CELGCelgene Corporation
16/10/201912h00Business WireCelgene & the Multiple Sclerosis Association of America Take the MS MindShift Initiative & “Brain Bulb” Hot Air Balloon t...NASDAQ:CELGCelgene Corporation
20/09/201913h30Business WireCelgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant RecipientsNASDAQ:CELGCelgene Corporation
12/09/201922h30Business WireCelgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myel...NASDAQ:CELGCelgene Corporation
11/09/201918h24Dow Jones NewsSwiss Biotech Anokion Raises $40 Million in Series B RoundNASDAQ:CELGCelgene Corporation
09/09/201913h30Business WireData from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress...NASDAQ:CELGCelgene Corporation
27/08/201909h02Dow Jones NewsCelgene, Bristol Clear Way For Merger -- WSJNASDAQ:CELGCelgene Corporation
26/08/201917h14Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 Billion--UpdateNASDAQ:CELGCelgene Corporation
26/08/201913h49Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 Billion -- UpdateNASDAQ:CELGCelgene Corporation
26/08/201913h14Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 BillionNASDAQ:CELGCelgene Corporation
26/08/201912h30PR Newswire (US)Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefi...NASDAQ:CELGCelgene Corporation
21/08/201914h45InvestorWireRecord Revenues, Milestone Achievements Indicate Strength, Potential of Biotech SectorNASDAQ:CELGCelgene Corporation
 Showing the most relevant articles for your search:NASDAQ:CELG

Dernières Valeurs Consultées

TSXV
SUU.H
Strathmore Plus Energy
USOTC
TSIOF
361 Degrees (PK)
DBI
4N67
DAXsubsector All Industr...
NYSE
MTBL
Moatable
BIT
FT613L
Vontobel
NYSE
KCT
Str PD 7.5 Sher-Will
NASDAQ
STRR
Star Equity
GATE
CHZUSD
chiliZ
USOTC
HLOC
Helo (PK)
LSE
GGK
Gamingking
LATK
ILVUSDT
Illuvium
GDAX
ATOMBTC
Cosmos Atom
ASX
KBUNA
ASX
DET
Dealt
MRTX
EXRNUSDT
EXRNchain
NASDAQ
RLOC
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés